Existing treatments for major depressive disorder (MDD) may require several weeks to months to exert their maximal benefit. Ketamine, a high-affinity NMDA glutamate receptor antagonist, is an anesthetic and analgesic medication commonly used in pediatric and adult patients. Ketamine has antidepressant properties in animal models, and may have rapid antidepressant activity for patients with severe mood disorders. A recent placebo-controlled investigation in patients with treatment-resistant unipolar depression (TRD) showed robust antidepressant efficacy of a single subanesthetic dose of intravenous (IV) ketamine (0.5 mg/kg), findings which replicated a previous small pilot trial. Strikingly, a high proportion of patients maintained the acute response to IV ketamine for several days or longer. In this 4-year single-site study, we will conduct a triple-masked, randomized, parallel-arm active control investigation of the acute efficacy and safety of IV ketamine in TRD.
Specific Aims : (1) To test whether a single IV infusion of ketamine has superior antidepressant efficacy compared to an active control agent (IV midazolam) in patients with TRD. (2) To characterize the durability of benefit and test whether IV ketamine is associated with superior antidepressant effects at the 7-day timepoint. (3) To examine the safety and tolerability of the interventions. The intent-to-treat sample is comprised of 64 TRD patients, conservatively defined as insufficient response to 7 3 adequate antidepressant trials in the current episode. After a medication-free period 7 2 weeks, patients are randomized to receive an infusion of either IV ketamine (0.5 mg/kg over 40 min) or IV midazolam (0.045 mg/kg over 40 min). Efficacy and safety is evaluated over the following 7 days. Nonresponders at the 7-day endpoint exit the study, while patients meeting response criteria are followed bi-weekly until relapse or for an additional 4 weeks. The primary efficacy measure is reduction in depression severity as assessed by the Montgomery- Asberg Depression Rating Scale (MADRS) scale 24 hours following IV infusion;additional outcome measures include response and remission rates, durability of benefit (7-day endpoint), side effects, and adverse events.
Significance: There is an urgent public health imperative to develop safe, well-tolerated, and rapidly-acting treatments for MDD. This research proposal seeks to benefit the public health by identifying a novel therapy for highly symptomatic and treatment-resistant patients that may decrease the morbidity and mortality associated with this common and serious illness.
|Price, Rebecca B; Iosifescu, Dan V; Murrough, James W et al. (2014) Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31:335-43|
|Haile, C N; Murrough, J W; Iosifescu, D V et al. (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:331-6|
|Dakwar, E; Anerella, C; Hart, C L et al. (2014) Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 136:153-7|
|Mathew, Sanjay J (2013) Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry 74:710-1|
|Chang, Lee C; Raty, Sally R; Ortiz, Jaime et al. (2013) The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther 19:390-5|
|Murrough, James W; Iosifescu, Dan V; Chang, Lee C et al. (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134-42|
|Mathew, Sanjay J; Shah, Asim; Lapidus, Kyle et al. (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26:189-204|